References
- 1. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia 2003; 9 Suppl 1: 10V7.
- 2. Stonebraker JS, Brooker M, Amand RE, et al. A study of reported factor VIII use around the world. Haemophilia 2010; 16W1X: 33V46.10.1111/j.1365-2516.2009.02131.x
- 3. MancoVJohnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357W6X: 535V44.
- 4. National Hemophilia Foundation Medical Bulletin 1994, 193.
- 5. World Health Organization. Report of a joint WHO and WFH Meeting on the control of hemophilia: Modern treatment of hemophilia. WHO; Geneva, 1994.
- 6. KruseVJarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013; 19 Suppl 1: 2V7.
- 7. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasmaVderived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8W6X: 1256V65.
- 8. Santagostino E, Morfini M, Auerswald GK, et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia 2009; 15W5X: 983V9.10.1111/j.1365-2516.2009.01999.x
- 9. Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000; 84W1X: 145V6.
- 10. Lenk H; ITT Study Group. The German Registry of immune tolerance treatment in hemophiliaVV1999 update. Haematologica 2000; 85W10 SupplX: 45V7.
- 11. Ettingshausen CE, Kreuz W. The immune tolerance induction WITIX dose debate: does the International ITI Study provide a clearer picture? Haemophilia 2013; 19 Suppl 1: 12V7.
- 12. Brackmann HH, Schwaab R, Effenberger W, et al. Antibodies to factor VIII in hemophilia A patients. Vox Sang 2000; 78 Suppl 2: 187V90.
- 13. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16 Suppl 1: S27V31.10.1097/01.mbc.0000167660.30886.e9
- 14. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7W4X: 375V80.10.1046/j.1365-2516.2001.00530.x
- 15. Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 2003; 88W6X: EREP03.
- 16. Suzuki T, Arai M, Amano K, et al. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996;76W5X: 749V54.
- 17. Gensana M, Altisent C, Aznar JA, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7W4X: 369V74.10.1046/j.1365-2516.2001.00526.x
- 18. Astermark J, Voorberg J, Lenk H, et al. Impact of inhibitor epitope profile on the neutralizing effect against plasmaVderived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9W5X: 567V72.10.1046/j.1365-2516.2003.00802.x
- 19. Inoue T, Shima M, Takeyama M, et al. Higher recovery of factor VIII WFVIIIX with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 2006; 12W1X: 110V3.10.1111/j.1365-2516.2006.01182.x
- 20. Kreuz W, EscuriolaVEttingshausen C, Auerswald G, et al. Immune tolerance induction WITIX in haemophilia A V patients with inhibitors V the choice of concentrate affecting success. Haematologica 2001; 86WS4X: 16V22.
- 21. Auerswald G, Spranger T, Brackmann HH. The role of plasmaVderived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88W6X: EREP05.
- 22. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96W5X: 1698V702.
- 23. Teitel JM, Barnard D, Israels S, et al. Home management of haemophilia. Haemophilia 2004; 10W2X: 118V33.
- 24. Soucie JM, Symons J 4th, Evatt B, et al. HomeVbased factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7W2X: 198V206.10.1046/j.1365-2516.2001.00484.x
- 25. Kurth MA, Dimichele D, Sexauer C, et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14W1X: 50V5.